An odious combination

Svechnikova E.V.; Zhufina S.E.

Свечникова Е.В.

Медицинский институт непрерывного образования ФГБОУ ВО «Росбиотех»;
ФГБУ «Поликлиника №1» УД Президента РФ

Жуфина С.Е.

ФГБУ «Поликлиника №1» Управления делами Президента Российской Федерации, Москва, Россия, 119002

Одиозная комбинация

Авторы:

Свечникова Е.В., Жуфина С.Е.

Подробнее об авторах

Журнал: Non nocere. Новый терапевтический журнал. 2025;(4): 26‑33

Прочитано: 251 раз

Связаться с автором

Оглавление

Как цитировать:

Свечникова Е.В., Жуфина С.Е. Одиозная комбинация. Non nocere. Новый терапевтический журнал. 2025;(4):26‑33.
Svechnikova EV, Zhufina SE. An odious combination. Non Nocere. New Therapeutic Journal. 2025;(4):26‑33. (In Russ.)

Использование инфографики авторами научных работ

Литература / References:

Torosian K, Lal E, Kavanaugh A, Loomba R, Ajmera V, Guma M. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Semin Arthritis Rheum. 2023 Apr;59:152165. https://doi.org/10.1016/j.semarthrit.2023.152165
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021 Aug 1;157(8):940-946. https://doi.org/10.1001/jamadermatol.2021.2007
Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. https://doi.org/10.3390/ijms20061475
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377-390. https://doi.org/10.1016/j.jaad.2016.07.064
Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021 May 13;184(10):2537-2564. https://doi.org/10.1016/j.cell.2021.04.015
Mrowietz U, Lauffer F, Sondermann W, Gerdes S, Sewerin P. Psoriasis as a Systemic Disease. Dtsch Arztebl Int. 2024 Jul 12;121(14):467-472. https://doi.org/10.3238/arztebl.m2024.0064
Hagenström K, Müller K, Garbe C, Augustin M. Prevalence of psoriasis and psoriatic arthritis in Germany – analysis of claims data. J Dtsch Dermatol Ges. 2024 Jan;22(1):45-54. https://doi.org/10.1111/ddg.15269
Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011 Aug;270(2):147-157. https://doi.org/10.1111/j.1365-2796.2010.02310.x
Российское общество дерматовенерологов и косметологов. Клинические рекомендации. Псориаз. Год утверждения: 2023. Дата обращения: 20.03.2025. https://www.rodv.ru/upload/iblock/a84/q6gxj2hn1mip4m1vaaqg1vyvsy05u11y.pdf
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021 Apr 3;397(10281):1301-1315. https://doi.org/10.1016/S0140-6736(20)32549-6
Prinz I, Sandrock I, Mrowietz U. Interleukin-17 cytokines: Effectors and targets in psoriasis – A breakthrough in understanding and treatment. J Exp Med. 2020 Jan 6;217(1): e20191397. https://doi.org/10.1084/jem.20191397
Puig L, Costanzo A, Muñoz-Elías EJ, Jazra M, Wegner S, Paul CF, Conrad C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022 May;186(5):773-781. https://doi.org/10.1111/bjd.20963
Kocaaga A, Kocaaga M. Psoriasis: An Immunogenetic Perspective. Glob Med Genet. 2022 Jun 13;9(2):82-89. https://doi.org/10.1055/s-0042-1743259
Kuiper JJ, Prinz JC, Stratikos E, et al. EULAR study group on ‘MHC–I-opathy’: identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis. 2023 Jul;82(7):887-896. https://doi.org/10.1136/ard-2022-222852
Andrees V, Wolf S, Augustin M, Mohr N, Augustin J. Regional variations and prevalence of psoriasis in Germany from 2010 to 2017: a cross-sectional, spatio-epidemiological study on ambulatory claims data. BMJ Open. 2021 Nov 16;11(11): e047806. https://doi.org/10.1136/bmjopen-2020-047806
Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):281-317. https://doi.org/10.1111/jdv.16926
Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis – time for a paradigm change. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):824-834. https://doi.org/10.1111/jdv.16866
Torres T, Chiricozzi A, Puig L, et al. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. Am J Clin Dermatol. 2024 Mar;25(2):333-342. https://doi.org/10.1007/s40257-024-00845-4
MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets – 2017. MMWR Morb Mortal Wkly Rep. 2019 Mar 22;68(11):263-266. https://doi.org/10.15585/mmwr.mm6811a3
Robert M, Miossec P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell Mol Immunol. 2021 Jul;18(7):1644-1651. https://doi.org/10.1038/s41423-021-00694-9
LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis. 2017 Oct;17(10):e327–e333. https://doi.org/10.1016/S1473-3099(17)30248-7
Lynch M, Roche L, Horgan M, Ahmad K, Hackett C, Ramsay B. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017 Apr 14;3(3):230-232. https://doi.org/10.1016/j.jdcr.2017.02.001
Snast I, Bercovici E, Solomon-Cohen E, et al. Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review. Am J Clin Dermatol. 2019 Aug;20(4):483-491. https://doi.org/10.1007/s40257-019-00432-y
Singh S, Maniakis-Grivas G, Singh UK, et al. Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis. J Pathol. 2018 Mar;244(3):311-322. https://doi.org/10.1002/path.5013
Ardain A, Domingo-Gonzalez R, Das S, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019 Jun;570(7762):528-532. https://doi.org/10.1038/s41586-019-1276-2
Huang YW, Tsai TF. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf. 2020 Apr;19(4):395-402. https://doi.org/10.1080/14740338.2020.1736034
Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis. Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):23-28. https://doi.org/10.1159/000501989
Megna M, Patruno C, Bongiorno MR, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. J Dermatolog Treat. 2022 Aug;33(5):2629-2633. https://doi.org/10.1080/09546634.2022.2062280
Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol. 2020 Nov;83(5):1436-1439. https://doi.org/10.1016/j.jaad.2020.06.012
Manzanares N, Vilarrasa E, López A, et al. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e26–e28. https://doi.org/10.1111/jdv.19406
Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111. https://doi.org/10.1186/s13075-019-1882-2
Leonardi C, Reich K, Foley P, et al. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. https://doi.org/10.1007/s13555-020-00367-x
Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018 Sep;179(3):615-622. https://doi.org/10.1111/bjd.16724